Background/Aims: This study aimed at investigating if M235T polymorphism in the AGT gene and A/GI8-83 polymorphism in the REN gene correlate with end-stage renal disease (ESRD). Methods: We analyzed 173 ESRD patients and 329 individuals with normal kidney function for differences in the genotype distribution of AGT-M235T and REN-A/GI8-83 polymorphisms between the two groups. The data for cases and controls were compared using the χ2 test. Results: We found significantly higher levels of serum creatinine and CRP in cases in comparison to controls (p < 0.0001). Data comparison showed a significant association of AGT M235T substitution with ESRD in the dominant model (p = 0.008) and in the comparison of the heterozygous substitution with the homozygous common genotype (p = 0.005). Similarly, REN A/GI8-83 polymorphism showed a significant difference in the distribution of genotypes between cases and controls (p < 0.038) such that a heterozygous substitution was significantly more common in the ESRD cases in comparison to the homozygous common genotype (p = 0.023). Conclusion: We conclude that heterozygous substitutions at the AGT M235T and REN A/GI8-83 loci correlate significantly with ESRD in a north Indian population.

Keywords:
End-stage renal disease, REN gene, AGT gene, Renin-angiotensin system
1.
Pontremoli R, Ravera M, Viazzi F, Nicolella C, Berruti V, Leoncini G, Giacopelli F, Bezante GP, Sacchi G, Ravazzolo R, Deferrari G: Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension. Kidney Int 2000;57:561-569.
2.
Parving HH, Osterby R, Ritz E: Diabetic nephropathy; in Brenner BM, Levine S (eds): The Kidney, ed 6. Philadelphia, WB Saunders, 2000, pp 1731-1773.
3.
Ritz E, Dikow R: Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2006;2:562-567.
4.
Mehri S, Mahjoub S, Farhati A, Bousaada R, Ben Arab S, Baudin B, Hammami M: Angiotensinogen gene polymorphism inacute myocardial infarction patients. J Renin Angiotensin Aldosterone Syst 2011;12:42-47.
5.
Thangaraj K, Joshi MB, Reddy AG, Gupta NJ, Chakravarty B, Singh L: CAG repeat expansion in the androgen receptor gene is not associated with male infertility in Indian populations. J Androl 2002;23:815-818.
6.
Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A, Kubo H, Kawaguchi Y, Kon V, Matsuoka K, Ichikawa I, Sakai O: Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 1996;50:657-664.
7.
Young RP, Chan JC, Critchley JA, Poon E, Nicholls G, Cockram CS: Angiotensinogen T235 and ACE insertion/deletion polymorphisms associated with albuminuria in Chinese type 2 diabetic patients. Diabetes Care 1998;21:431-437.
8.
Wang J, Zhu X, Yang L, Liu Y, Zhou W, Li H: Relationship between angiotensinogen gene M235T variant with diabetic nephropathy in Chinese NIDDM. Chin Med J (Engl) 1999;112:797-800.
9.
Wu S, Xiang K, Zheng T, Sun D, Weng Q, Zhao H, Li J: Relationship between the renin-angiotensin system genes and diabetic nephropathy in the Chinese. Chin Med J (Engl) 2000;113:437-441.
10.
Chang HR, Cheng CH, Shu KH, Chen CH, Lian JD, Wu MY: Study of the polymorphism of angiotensinogen, angiotensin-converting enzyme and angiotensin receptor in type II diabetes with end-stage renal disease in Taiwan. J Chin Med Assoc 2003;66:51-56.
11.
Fogarty DG, Harron JC, Hughes AE, Nevin NC, Doherty CC, Maxwell AP: A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes 1996;45:1204-1208.
12.
Eroğlu Z, Cetinkalp S, Erdogan M, Kosova B, Karadeniz M, Kutukculer A, Gunduz C, Tetik A, Topcuoglu N, Ozgen AG, Tuzun M: Association of the angiotensinogen M235T and angiotensin-converting enzyme insertion/deletion gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. J Diabetes Complications 2008;22:186-190.
13.
Reis KA, Ebinç FA, Koç E Demirci H, Erten Y, Güz G, Derici UB, Bali M, Söylemezoğlu O, Arınsoy T, Sindel S: Association of the angiotensinogen M235T and APO e gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. Ren Fail 2011;33:469-474.
14.
Hunley TE, Julian BA, Phillips JA 3rd, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V: Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996;49:571-577.
15.
Schmidt S, Stier E, Hartung R, Stein G, Bahnisch J, Woodroffe AJ, Clarkson AR, Ponticelli C, Campise M, Mayer G, et al: No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 1995;26:727-731.
16.
Pei Y, Scholey J, Thai K, Suzuki M, Cattran D: Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 1997;100:814-820.
17.
Basset E, Berthoux P, Cecillon S, Deprle C, Thibaudin D, De Filippis JP, Alamartin E, Berthou F: Hypertension after renal transplantation and polymorphism of genes involved in essential hypertension: ACE, AGT, AT1 R and ecNOS. Clin Nephrol 2002;57:192-200.
18.
Lee KB, Kim UK: Angiotensinogen and angiotensin II type 1 receptor gene polymorphism in patients with autosomal dominant polycystic kidney disease: effect on hypertension and ESRD. Yonsei Med J 2003;44:641-647.
19.
Papp F, Friedman AL, Bereczki C, Haszon I, Kiss E, Endreffy E, Túri S: Renin-angiotensin gene polymorphism in children with uremia and essential hypertension. Pediatr Nephrol 2003;18:150-154.
20.
Zhou TB, Yin SS, Qin YH: Association of angiotensinogen M235T gene polymorphism with end-stage renal disease risk: a meta-analysis. Mol Biol Rep 2013;40:765-772.
21.
Okura T, Kitami Y, Hiwada K: Restriction fragment length polymorphisms of the human renin gene: association study with a family history of essential hypertension. J Hum Hypertens 1993;7:457-461.
22.
Frossard PM, Lestringant GG, Elshahat YI, John A, Obineche EN: An MboI two-allele polymorphism may implicate the human renin gene in primary hypertension. Hypertens Res 1998;21:221-225.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.